[Eczema vaccinatum. (Report of a case)].
Explore the source record for details and available documents.
Eczema↗
Biomedical subjects
D Gómez Barreto
Publications and source records attributed to D Gómez Barreto.
[Tracheotomy].
This work deals with a review of the main aspects involved in the practice of tracheostomy which could be considered an easy procedure; however, the fact is that errors are continuously observed when it is indicated or performed; likewise, many mistakes are made during the care of the patient with a tracheostomy. If all this aspects are of importance in the adult, this importance increases in the child because of the great anatomical and physiological differences which always should be kept in mind in order to avoid complications of the procedure.
Female↗
[Safety and efficacy of OM-85-BV plus amoxicillin/clavulanate in the treatment of subacute sinusitis and the prevention of recurrent infections in children].
A 6-month double-blind, prospective, randomized, placebo-controlled trial was conducted to establish the safety and efficacy of OM-85-BV in the treatment of subacute sinusitis and in the following prevention of the respiratory tract infections in 56 children from 18 months to 9 years of age. In the subacute phase of the sinusitis the patients were given one OM-85-BV capsule (3.5 mg of bacterial extracts) (n = 26) or placebo (n = 30), daily for ten days; additionally both groups took amoxicillin/clavulanate 40/10 mg/kg daily in three divided doses for 21 days. For the following two months the patients took one OM-85-BV capsule or placebo, ten days a month. In the subacute phase the OM-85-BV group of patients improved sooner (5.56 +/- 4.98 vs 10 +/- 8.49 days) and had a shorter convalescence (15.38 +/- 8.91 vs 20.28 +/- 7.17 days). During the six month follow-up the patients in the OM-85-BV group had a lower number of infections (1.56 +/- 0.3 vs 2.22 +/- 0.43) and required a lower number of drug treatments (1.47 +/- 0.32 vs 1.94 +/- 0.42). One patient treated with OM-85-BV presented a mild rash which disappeared three days after the drug discontinuation. We conclude that OM-85-BV is safe at pediatric ages, as well as accelerates the cure and improvement of subacute sinusitis while it lowers the incidence of respiratory infections.
Adjuvants, Immunologic↗